PT  - JOURNAL ARTICLE
AU  - Zimmermann, Mona LM
AU  - Breedt, Lucas C
AU  - Centeno, Eduarda GZ
AU  - Reijneveld, Jaap C
AU  - Santos, Fernando AN
AU  - Stam, Cornelis J
AU  - van Lingen, Marike R
AU  - Schoonheim, Menno M
AU  - Hillebrand, Arjan
AU  - Douw, Linda
TI  - The relationship between pathological brain activity and functional network connectivity in glioma patients
AID  - 10.1101/2023.04.20.23288814
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.20.23288814
4099  - http://medrxiv.org/content/early/2023/04/26/2023.04.20.23288814.short
4100  - http://medrxiv.org/content/early/2023/04/26/2023.04.20.23288814.full
AB  - Background Glioma is associated with pathologically high peritumoral brain activity, which relates to faster progression. Functional connectivity is disturbed locally and throughout the entire brain, associating with symptomatology. We, therefore, investigated how local activity and network measures relate to better understand how the intricate relationship between the tumor and the rest of the brain may impact disease and symptom progression.Methods We obtained magnetoencephalography in 84 de novo glioma patients and 61 matched healthy controls. The offset of the power spectrum, a proxy of neuronal activity, was calculated for 210 cortical regions. We calculated patients’ regional deviations in delta, theta and lower alpha network connectivity as compared to controls, using two network measures: clustering coefficient, a measure of local connectivity, and eigenvector centrality (integrative connectivity). We then tested group differences in activity and connectivity between peritumoral, contralateral homologue regions, and the rest of the brain. We also correlated regional offset to connectivity.Results As expected, patients’ peritumoral activity was pathologically high, and patients showed higher clustering and lower centrality than controls. At the group-level, regionally high activity related to high clustering in controls and patients alike. However, within-patient analyses revealed negative associations between regional deviations in brain activity and clustering, such that pathologically high activity coincided with low network clustering, while regions with ‘normal’ activity levels showed high network clustering.Conclusions Our results indicate that pathological activity and connectivity co-localize in a complex manner in glioma. This insight is relevant to our understanding of disease progression and cognitive symptomatology.KeypointsRegional activity and network clustering are pathologically high in gliomaHowever, high-activity regions show low clustering and vice versaThis finding could be relevant to understand functioning and prognosis in gliomaImportance of the study Glioma patients show high peritumoral brain activity, which relates to faster tumor progression. Moreover, patients have local and global functional network disturbances, which associate with cognitive dysfunction and other symptoms. However, how such activity and network deviations correlate across and within patients is unclear. We, therefore, studied a large cohort of newly diagnosed glioma patients and matched healthy controls, extracting activity and connectivity from the entire cortex. We find a surprising relationship between deviations in activity and local clustering: while higher activity and clustering go hand in hand in controls, the pathologically high activity we observe in individual glioma patients coincides with exceedingly low clustering, while areas with normal activity levels have pathologically high clustering. These insights indicate an intricate relationship between aberrant activity and connectivity throughout the brain in glioma. It remains to be seen how this complex relationship impacts tumor growth and potentially cognitive deficits.Competing Interest StatementMona LM Zimmermann: None declared Lucas C Breedt: None declared Eduarda GZ Centeno: None declared Jaap C Reijneveld: Payment for educational event: iMeedu Teaching course Noord-Noordhollandse Neurologen, iMeedu Teaching course Het Centrale Brein Support for attending meetings or travel: Arvelle Therapeutics (manufacturer of anti-seizure medication Cenobamate), attended European Epilepsy Congress in Geneva, 2023 Fernando AN Santos: None declared Cornelis J Stam: None declared Marike R van Lingen: Grants or contracts from any entity: MEGIN Menno M Schoonheim: Grants or contract from any entity: Dutch MS foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS, ZonMW (Vidi grant 09150172010056) Consulting fees: Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, Genzyme, MedDay, Merck On the editorial board of: Neurology and Frontiers in Neurology Arjan Hillebrand: Grants or contracts from any entity: MEGIN, KWF Dutch Cancer Society Linda Douw: Grants or contracts from any entity: MEGIN Funding StatementNederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) Veni (016.146.086); Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) Vidi (198.015); Branco Weiss Fellowship; Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding (KWF) (12885);Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Ethics Committee of the the Vrije Universiteit Medical Center (Amsterdam University Medical Center) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll scripts used to analyse the data can be openly accessed on our github repository: https://github.com/multinetlab-amsterdam/projects/tree/master/activity_network_project_2023